45 results about "Acute exacerbation of chronic obstructive pulmonary disease" patented technology

The invention relates to Chinese medicinal compound granules for treating acute exacerbation of chronic obstructive pulmonary disease, which can effectively solve the problem of treatment medication of the acute exacerbation of the chronic obstructive pulmonary disease. The granules are prepared from pepperweed seed, earthworm, thunberg fritillary bulb, prepared rhubarb, mix-fried ephedra herb, red paeony root, Japanese ardisia herb, ginseng, dwarf lilyturf tuber, grassleaf sweelflag rhizome and sugar powder. The Chinese medicinal compound granules are obtained by (1) crushing the ginseng into fine powder; (2) adding water into the grassleaf sweelflag rhizome, distilling the grassleaf sweelflag rhizome to extract volatile oil, filtering liquid, and preserving the liquid; (3) mixing the pepperweed seed, the earthworm, the thunberg fritillary bulb, the prepared rhubarb, the mix-fried ephedra herb, the red paeony root, the Japanese ardisia herb and the dwarf lilyturf tuber, adding water and decocting the mixture to obtain filtrate, merging filter residue and filter residue of the grassleaf sweelflag rhizome, adding water and decocting the mixture to obtain filtrate, merging the filtrate obtained twice, merging with the grassleaf sweelflag rhizome liquid, and concentrating the mixture under reduced pressure until forming thick paste; (4) adding the thick paste into the sugar powder and the ginseng fine powder, and mixing, granulating, drying and palletizing the mixture; and (5) spraying the grassleaf sweelflag rhizome volatile oil, uniformly mixing the mixture, and airtightly placing and subpacking the mixture. The Chinese medicinal compound granules can obviously improve clinical symptoms and physical signs of patients, and improve the function of pulmonary ventilation.

The invention provides traditional Chinese medicine composition for treating the stationary-phase COPD (chronic obstructive pulmonary disease). The composition comprises raw materials in parts by weight as follows: 47 parts of codonopsis radix, 59 parts of light wheat, 35 parts of fried largehead atractylodes rhizome, 23 parts of prepared pinellia tuber, 47 parts of dried tangerine peel, 35 parts of perilla fruit, 35 parts of divaricate saposhnikovia root, 35 parts of poria cocos, 59 parts of raw coix seed, 35 parts of honey-fried common coltsfoot flower, 35 parts of baical skullcap root, 35 parts of bulbus fritillariae pallidiflorae and 35 parts of honey-fried loquat leaf. The traditional Chinese medicine composition can prolong the second-time acute exacerbation time interval of a COPD patient by 77.68 days, decrease acute exacerbation times by 1.46 times per half a year, shorten the acute exacerbation duration by 2.93 days, decrease mMRC and CAT scores, improve clinical symptoms such as coughing, expectoration, shortness of breath, spontaneous perspiration, lacking in strength and the like, and enhance the exercise tolerance (that is, the 6MWD is increased). The composition has no side effect in a taking process of the clinical patient, so that the composition is a safe and effective prescription for treating the stationary-phase COPD.

The invention discloses a system for identifying acute exacerbation of chronic obstructive pulmonary disease, which comprises a computer memory, a computer processor and a computer program which is stored in the computer memory and can be executed on the computer processor, and the following modules are stored in the computer memory: a data characteristic processing module which is used for receiving the pneumology department doctor-seeing data for feature processing and generating data applied to the recognition module; and a recognition module which is used for receiving the data sent by the data feature processing module and predicting whether the target patient is in the acute exacerbation stage of the chronic obstructive pulmonary disease. By utilizing the system, the efficiency of identifying acute exacerbation of the chronic obstructive pulmonary disease can be improved while the examination time is shortened.

Provided is a system for predicting an acute exacerbation of COPD. The system, combined with a stored application, including a collection unit gathering variables from a medical record integration server, a virus information server, a weather data server, and a social data server and generating specifications constituted of a data set including of the variables at every point of time when the variables occurred in response to a prediction request on the occurrence of an acute exacerbation of COPD in patient, a model configuration unit determining variables and coefficients of the parameters connected to the variables to set a prediction model, an analysis unit inputting the variables of the specification and the parameter coefficients to the model set by the model configuration unit to predict an occurrence of the acute exacerbation of the COPD in patient, a providing unit providing a prediction result value to at least one client.

The invention discloses a drug for a stable stage of chronic obstructive pulmonary diseases and a preparation method thereof. The medicinal effective components are composed of radix astragali preparata, sun-dried ginseng, bulbus Lily, cortex lycii, herba ephedrae preparata, semen armeniacae amarum, rhizoma atractylodis, gecko, bulbus fritillariae thunbergii, seeds of snake gourds, radix trichosanthis, poria cocos, dried orange peels, radix platycodi, rhizoma pinelliae preparata, radix glycyrrhizae preparata, rhizoma alismatis, cortex moutan and radix paeoniae rubra. The drug has the effects of tonifying deficiency (invigorating qi-yin of the lung and invigorating qi of the spleen and kidney), eliminating phlegm, removing dampness, facilitating diuresis, promoting blood circulation, removing blood stasis, nourishing yin, clearing away internal heat, ventilating the lung and unclogging the viscera. The drug can be used in the stable stage of chronic obstructive pulmonary diseases, improve immunity, reduce the frequency of acute aggravation induced by infection, improve the lung function, promote oxygenation, control the disease progress and relieve cough, expectoration, asthma, anddyspnea.

The invention relates to a traditional Chinese medicine prescription for treating pulmonary diseases, which comprises lapis chloriti, roasted ephedra, almond, schisandra, snakegourd peel and roasted licorice. Experiments prove that the traditional Chinese medicine prescription can obviously improve the pulmonary lesion and inflammatory reaction of a model rat with the chronic obstructive pulmonary disease at the acute exacerbation, so as to obviously reduce the contents of main inflammatory markers in the serum of the model rat, and simultaneously can promote the trachea repair of the model rat so as to prevent the occurrence and development of trachea inflammation. Clinical researches show that the traditional Chinese medicine prescription has a good effect and a high effect taking speed when being used for treating empirical pulmonary diseases, such as accumulation of pathogenic heat in the lung and obstruction of the lung by phlegm; the good effect can be achieved within 3-10 days, and the total effective rate reaches 96.6%; the traditional Chinese medicine prescription especially has good curative effects on chronic intractable pulmonary diseases induced by pathogenic heat and stubborn phlegm; the traditional Chinese medicine prescription does not have toxic or side effects; and the pulmonary diseases can not recur.

The invention belongs to the field of medicines, and particularly relates to a production method of an acute exacerbation chronic heart failure animal model. The acute exacerbation chronic heart failure model is built according to double factors of a clinical cause and a clinical inducement, on one hand, the acute exacerbation chronic heart failure model has the cause of a pathological disease basis myocardial infarction of chronic heart failure, and on the other hand, the acute exacerbation chronic heart failure model has the inducement of a body fluid load on the basis of the cause. The model shows two major characteristics of heart failure exacerbation after being produced successfully, wherein the two major characteristics refer to further reduction of a systolic function on the basisthat the systolic function is already weakened, and respiration function index change similar to clinical symptoms. The model can be used for studies of effectiveness of a novel medicine, the action mechanism of the novel medicine and the like.

The invention relates to Chinese medicinal compound granules for treating acute exacerbation of chronic obstructive pulmonary disease, which can effectively solve the problem of treatment medication of the acute exacerbation of the chronic obstructive pulmonary disease. The granules are prepared from pepperweed seed, earthworm, thunberg fritillary bulb, prepared rhubarb, mix-fried ephedra herb, red paeony root, Japanese ardisia herb, ginseng, dwarf lilyturf tuber, grassleaf sweelflag rhizome and sugar powder. The Chinese medicinal compound granules are obtained by (1) crushing the ginseng into fine powder; (2) adding water into the grassleaf sweelflag rhizome, distilling the grassleaf sweelflag rhizome to extract volatile oil, filtering liquid, and preserving the liquid; (3) mixing the pepperweed seed, the earthworm, the thunberg fritillary bulb, the prepared rhubarb, the mix-fried ephedra herb, the red paeony root, the Japanese ardisia herb and the dwarf lilyturf tuber, adding water and decocting the mixture to obtain filtrate, merging filter residue and filter residue of the grassleaf sweelflag rhizome, adding water and decocting the mixture to obtain filtrate, merging the filtrate obtained twice, merging with the grassleaf sweelflag rhizome liquid, and concentrating the mixture under reduced pressure until forming thick paste; (4) adding the thick paste into the sugar powder and the ginseng fine powder, and mixing, granulating, drying and palletizing the mixture; and (5) spraying the grassleaf sweelflag rhizome volatile oil, uniformly mixing the mixture, and airtightly placing and subpacking the mixture. The Chinese medicinal compound granules can obviously improve clinical symptoms and physical signs of patients, and improve the function of pulmonary ventilation.

The invention provides a medicinal preparation used for treating acute exacerbation of chronic obstructive pulmonary disease. Raw medicines used in the invention comprise Salvia miltiorrhiza, Agrimonia eupatoria, Polygonatum sibiricum, Rhizoma Curcumae, cassia twig, Fritillaria thunbergii Miq., White Mulberry Root-bark, Semen Euryales, Morinda parvifolia, Spina Gleditsiae, Geranium wilfordii Maxim., Aletris pauciflora var. khasiana, Silene conoidea L., Conyza japonica, Radix Asparagi, Herba Leucatis Molloissimae, Loquat leaf, Rhizoma Anemarrhenae, Radix Glehniae, Herbal Ephedrae, Snakegourd Fruit, Radix Morindae officinalis, Boswellia carteri, Yetbadetajo Hert, Hippophae rhamnoides, Rhizoma Polygoni Cuspidati, Changium smyrnioides, Bamboo Shavings, Acorus gramineus and cortex lycii. The medicinal preparation has the advantages of good treatment effect, improvement of the curing rate of patients, and few untoward effects, and deserves popularization and application.

The invention relates to a traditional Chinese medicine composition for treating acute exacerbation of chronic obstructive pulmonary disease and a preparation method thereof. The problem of medicationfor treatment of chronic obstructive pulmonary disease in the acute exacerbation stage can be effectively solved; the composition comprises the following raw materials: semen armeniacae amarae, gypsum, trichosanthes kirilowii maxim, rheum officinale, scutellaria baicalensis, fructus perillae, radix glycyrrhizae preparata, wild buckwheat and radix asteris. In the adopted preparation method, according to the characteristics of the effective componetns of the traditional Chinese medicine composition, gypsum is independently extracted; the formation of flavonoid and anthraquinone component complexes is reduced, the extraction efficiency of effective components is improved, single extraction of volatile oil, inclusion of hydroxypropyl-beta-cyclodextrin so as to retain volatile components, thepreparation process is reasonable and feasible, the content of effective components are high, blending is convenient, and granules, tablets, capsules, oral liquids and pills can be prepared. The traditional Chinese medicine composition disclosed by the invention can obviously improve the symptoms of fever, cough, expectoration, excessive phlegm, abdominal distension and constipation caused by acute exacerbation of chronic obstructive pulmonary diseases.

The invention relates to pharmaceutical compositions comprising 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide for use in the treatment of acute exacerbations of chronic obstructive pulmonary disease in human patients having <2% blood eosinophils. The invention also relates to pharmaceutical compositions for the treatment of AECOPD in a human patient having <2% blood eosinophils, comprising administering to the patient three separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide over a period of not longer than ten days with at least one day between every dose.

At present, western medicines are mainly adopted to treat acute exacerbation of chronic obstructive pulmonary diseases, but because of the lack of etiological treatment means, a patient has disease reoccurrence frequently in the treatment process and has the trend of progressive aggravation. Through theoretical exploration and experiment research, the inventor discloses a traditional Chinese medicine composition used in acute exacerbation of chronic obstructive pulmonary diseases. The traditional Chinese medicine composition comprises traditional Chinese medicines such as arisaema cum bile, rhizoma pinellinae praeparata and complete dried trichosanthes kirilowii maxim. The traditional Chinese medicine composition disclosed by the invention aims to etiological treatment and is reasonable incomponent matching. Clinical tests show that a definite treatment effect can be achieved, and a remarkable effect can be achieved when being compared with that of a control group.

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the invention relates to relates to a polypeptide selected from the group consisting of IL-22 polypeptides or IL-17 polypeptides for use in a method for the treatment of acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof.

The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for treating AECOPD (acute exacerbation of chronic obstructive pulmonary disease) wind-cold affecting lung syndrome. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 8-12g of poriacocos, 5-7g of liquorice, 8-10g of rhizoma zingiberis, 8-12g of pinellia ternate, 5-7g of herba asari cum radice, 5-7g of schisandra chinensis, and 8-10g of almond. According to the traditional Chinese medicine composition, the materials are accurately combined; the composition realizes contraction with dissipation and close within open; wind-pathogen is removed; the fluid retention is removed; the lung is induced and descended, and thus all syndromes are treated; all components in the formula are coordinated and acted to achieve the effects of warming lung and reducing fluid retention, depressing Qi and alleviating water retention; the composition is small in side effect, and good in treatment effect; the composition is obvious in effect of treating AECOPD syndromes like recurrent fluidretention caused by exogenous pathogenic factors, weak constitution, or electrolyte disturbance and asthmatic suffocating syndrome, poor appetite and constipation, impaired lung, unbalanced fluid channel, and limb edema.

The invention relates to a preparation for shortening the course of acute exacerbation of chronic obstructive pulmonary disease, which is prepared from the following raw materials: 10-20 parts of astragalus membranaceus granules, 7-17 parts of codonopsis pilosula granules, 4-13 parts of fried perilla fruit granules, 4-13 parts of semen lepidii granules, 7-17 parts of angelica sinensis granules, 10-20 parts of rhodiola rosea granules, 1-11 parts of schisandra chinensis granules, 4-13 parts of pericarpium citri reticulatae granules and 1-11 parts of polygala tenuifolia granules. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 4-13 parts of ginger-processed cortex magnoliae officinalis granules, 4-13 parts of rhizoma pinelliae preparata granules, 4-13 parts of radix curcumae granules, 4-13 parts of bulbus fritillariae thunbergii granules and 1-11 parts of herba The invention also discloses a preparation method of the preparation. The medication principle of the preparation is based on eliminating phlegm and blood stasis and tonifying qi and yin, and the rhodiola rosea has the effects of tonifying qi, activating blood, dredging pulse and relieving asthma and can effectively remove phlegm and blood stasis by being matched with the astragalus membranaceus as a monarch drug. Codonopsis pilosula and angelica sinensis are monarch drugs and have the effects of tonifying and benefiting qi. Stir-fried fructus perillae, semen lepidii, ginger processed cortex magnoliae officinalis, rhizoma pinelliae preparata, radix curcumae, bulbus fritillariae thunbergii and other adjuvant drugs are used for assisting the effects of the monarch drugs and the ministerial drugs, and schisandra chinensis, polygala tenuifolia, herba epimedii and pericarpium citri reticulatae are used as conductant drugs for harmonizing the drugs. The preparation provided by the invention can effectively shorten the course of acute exacerbation of sexual obstructive pulmonary disease and significantly improve clinical symptoms of patients.

The invention discloses a susceptible gene for acute exacerbation of chronic obstructive pulmonary disease and application of the susceptible gene in prediction of susceptible acute exacerbation of chronic obstructive pulmonary disease. Clinical specimens such as blood of a patient in the chronic obstructive pulmonary disease acute exacerbation stage are collected, blood circulation DNA whole exons of the COPD patient are detected through a genomics technology, and 20 AECOPD specific susceptibility genes are obtained by comparing the gene difference of the whole exons of the chronic obstructive pulmonary disease patient in the stable stage and the acute exacerbation stage; through gene detection of a verification queue, a highly specific gene for predicting acute exacerbation of chronic obstructive pulmonary disease is identified in the 20 genes, and can be used for screening susceptible patients with acute exacerbation of chronic obstructive pulmonary disease, so that a basis is provided for researching and verifying prognosis and recurrence markers of susceptible acute exacerbation of chronic obstructive pulmonary disease in a larger clinical sample in the future; wide application prospects are realized.

The invention relates to dosage regimens for administering pharmaceutical compositions comprising 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide for the treatment of a human patient suffering from COPD, or suffering from an acute exacerbation of COPD, or at risk of developing an acute exacerbation of COPD, or to prevent a reoccurrence of an acute exacerbation of COPD, or to prevent a treatment failure of an acute exacerbation of COPD, and to methods of prevention or reduction in the rate of acute exacerbations of COPD in a human patient.

The present invention relates to a novel composition or method of use for the treatment and / or the prevention of chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic obstructive pulmonary disease (AECOPDs).

The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for treating AECOPD (acute exacerbation of chronic obstructive pulmonary disease) phlegm-heat lung obstruction syndrome. The composition is prepared from the following components in parts by weight: 10-20g of radix asteris, 5-15g of angelica sinensis, 5-15g of almond, 8-20g of scutellaria baicalensis, 5-15g of raw ephedra, 5-15g of exocarpium, 5-15g of cassia twig, 5-15g of dutchmanspipe root, 1-5g of wine-treated rhubarb, and 3-10g of honey-fried licorice root. According to the composition, the radix asteris is capable of reducing phlegm and depressing Qi, clearing away the lung-heat and conditioning the fluid channel and is themain medicine in the formula; angelica sinensis is capable of relieving cough and smoothing Qi; cassia twig and raw ephedra are capable of opening inhibited lung-energy and relieving asthma to removeexogenous cold; scutellaria baicalensis is capable of clearing away lung heat; almond is capable of depressing Qi and reducing phlegm, and thus the effects of inducing and descending lung and regulating hot and cold are achieved; exocarpium and dutchmanspipe root are capable of guiding qi downward and reducing phlegm; the wine-treated rhubarb is capable of soothing Qi; the honey-fried licorice root is used for conditioning the medicines; all components are coordinated and acted in the formula to realize effects of opening inhibited lung-energy and clearing heat, reducing phlegm and depressingQi; the composition is free from toxic and side effects, and is fast to act and good in treatment effect.

The invention provides traditional Chinese medicine composition for treating the stationary-phase COPD (chronic obstructive pulmonary disease). The composition comprises raw materials in parts by weight as follows: 47 parts of codonopsis radix, 59 parts of light wheat, 35 parts of fried largehead atractylodes rhizome, 23 parts of prepared pinellia tuber, 47 parts of dried tangerine peel, 35 parts of perilla fruit, 35 parts of divaricate saposhnikovia root, 35 parts of poria cocos, 59 parts of raw coix seed, 35 parts of honey-fried common coltsfoot flower, 35 parts of baical skullcap root, 35 parts of bulbus fritillariae pallidiflorae and 35 parts of honey-fried loquat leaf. The traditional Chinese medicine composition can prolong the second-time acute exacerbation time interval of a COPD patient by 77.68 days, decrease acute exacerbation times by 1.46 times per half a year, shorten the acute exacerbation duration by 2.93 days, decrease mMRC and CAT scores, improve clinical symptoms such as coughing, expectoration, shortness of breath, spontaneous perspiration, lacking in strength and the like, and enhance the exercise tolerance (that is, the 6MWD is increased). The composition has no side effect in a taking process of the clinical patient, so that the composition is a safe and effective prescription for treating the stationary-phase COPD.

This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of inflammatory conditions.

This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

The oral liquid is prepared from ginseng, poria cocos, radix glycyrrhizae preparata, radix glehniae, rhizoma phragmitis, semen armeniacae amarae, folium perillae, platycodon grandiflorum, fructus arctii, rhizoma pinellinae praeparata, semen coicis, fructus amomi rotundus, fresh ginger, semen plantaginis and cortex magnoliae officinalis. According to the oral liquid for nourishing the lung and reducing phlegm, through comparison of test experiments of life quality self-evaluation, lung ventilation function test value, dyspnea index, six-minute walking test, traditional Chinese medicine symptom score, traditional Chinese medicine symptom score, phlegm excretion ability, weakness condition and adverse reaction occurrence condition, no adverse reaction is found. When the mode is applied to the acute exacerbation stage of the chronic obstructive pulmonary disease caused by deficiency of both qi and yin and phlegm-damp accumulation in the lung, the clinical effects of relieving asthma, resisting infection and reducing phlegm are relatively more remarkable compared with those of relieving asthma, resisting infection and reducing phlegm by only using conventional western medicines, and the combined lung-nourishing and phlegm-reducing oral liquid has obvious advantages. The life quality of a patient can be obviously improved, the dyspnea symptom is relieved, the sputum excretion capacity of the patient is improved, the diet condition and the weak state are improved, and the lung rehabilitation purpose is achieved.

The invention provides a kit for diagnosing acute exacerbation of a chronic obstructive pulmonary disease. The kit is characterized by comprising a cell enzyme labeled antibody of a cell factor; and the cell factor is a human lymphatic tissue chemokine (6Ckine), a macrophage-derived chemokine (MDC) and beta cytokine (BTC). In the kit, the human lymphatic tissue chemokine (6Ckine), the macrophage-derived chemokine (MDC) and the beta cytokine (BTC) are firstly provided to be main indexes of diagnosis of the acute exacerbation of the chronic obstructive pulmonary disease.